130365-87-6

Basic information

• Product Name: 1-(2-Bromoethyl)-4-(trifluoromethyl)benzene, 2-(4-Trifluoromethylphenyl)ethyl bromide
• Synonyms: 1-(2-Bromoethyl)-4-(trifluoromethyl)benzene, 2-(4-Trifluoromethylphenyl)ethyl bromide;4-(Trifluoromethyl)phenethyl bromide;4-TrifluoroMethylphenyl)ethyl broMide;1-(2-broMoethyl)-4-(trifluoroMethyl)benzene;4-(TrifluoroMethyl)phenethyl broMide 97%;2-(4-trifluoromethylphenyl)ethyl bromide
• CAS NO: 130365-87-6
• Molecular Formula: C₉H₈BrF₃
• Molecular Weight: 253.07
• Mol File: 130365-87-6.mol

Chemical Properties

• Boiling Point: 218.0±35.0 °C(Predicted)
• Appearance: /
• Density: 1.499 g/mL at 25 °C
• Refractive Index: n20/D 1.487
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(2-Bromoethyl)-4-(trifluoromethyl)benzene, 2-(4-Trifluoromethylphenyl)ethyl bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Bromoethyl)-4-(trifluoromethyl)benzene, 2-(4-Trifluoromethylphenyl)ethyl bromide(130365-87-6)
• EPA Substance Registry System: 1-(2-Bromoethyl)-4-(trifluoromethyl)benzene, 2-(4-Trifluoromethylphenyl)ethyl bromide(130365-87-6)

Safety Data

• Hazard Codes: Xn,N
• Statements: 22-36-51/53
• Safety Statements: 26-61
• RIDADR: UN 3082 9/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 130365-87-6(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
1-(2-Bromoethyl)-4-(trifluoromethyl)benzene and 2-(4-Trifluoromethylphenyl)ethyl bromide are used as intermediates or reactants in chemical synthesis for their reactivity and volatility. The bromine atom and the trifluoromethyl group allow for various chemical reactions to occur, making them valuable in the synthesis of complex molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-(2-Bromoethyl)-4-(trifluoromethyl)benzene and 2-(4-Trifluoromethylphenyl)ethyl bromide are used as building blocks for the synthesis of various complex molecules. Their unique properties and reactivity make them suitable for the development of new drugs and pharmaceutical compounds.
Used in Other Industries:
1-(2-Bromoethyl)-4-(trifluoromethyl)benzene and 2-(4-Trifluoromethylphenyl)ethyl bromide may also be used in other industries for the synthesis of complex molecules. Their versatility and reactivity make them valuable in various applications, such as in the production of specialty chemicals, materials, and other products.

Upstream product

• 32857-62-8 4-Trifluoromethylphenylacetic acid 
• 2968-93-6 2-(4-trifluoromethylphenyl)ethanol 
• 402-50-6 1-trifluoromethyl-4-vinyl-benzene 
• 455-19-6 4-Trifluoromethylbenzaldehyde 

Downstream Products

• 645413-93-0 tert-butyl 2-oxo-4-(4-(trifluoromethyl)phenyl)butanoate 
• 876926-08-8 2-iodo-1-{2-[4-(trifluoromethyl)phenyl]ethyl}-1H-imidazole 
• 178685-14-8 1-(2-iodoethyl)-4-(trifluoromethyl)benzene 
• 1058726-84-3 5-(4-(trifluoromethyl)phenyl)pentan-2-one 
• 1111733-58-4 N-(3,4-dimethylphenyl)-2-oxo-2-phenyl-N-(4-(trifluoromethyl)phenethyl)acetamide 
• 2968-93-6 2-(4-trifluoromethylphenyl)ethanol 

Relevant articles and documents

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

Scalable anti-Markovnikov hydrobromination of aliphatic and aromatic olefins

To improve access to a key synthetic intermediate we targeted a direct hydrobromination-Negishi route. Unsurprisingly, the anti-Markovnikov addition of HBr to estragole in the presence of AIBN proved successful. However, even in the absence of an added initiator, anti-Markovnikov addition was observed. Re-examination of early reports revealed that selective Markovnikov addition, often simply termed "normal" addition, is not always observed with HBr unless air is excluded, leading to the rediscovery of a reproducible and scalable initiator-free protocol.

FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS

The present invention provides fused thiophene and thiazole derivatives of formula (I), which may be therapeutically useful, more particularly as RORγ modulators; in which R1, R2, R3, R4, R5, R6, R7, X1, X2, L, m, n and ring A have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in disease(s) or disorder(s) where there is an advantage in modulating RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the fused thiophene and thiazole derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS

There is provided compounds of formula I, [Chemical formula should be inserted here. Please see paper copy] wherein R1 to R4 , R41 to R46 and Z have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias

NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS

There is provided compounds of formula (I), wherein R1, R2, R3, R4, R 41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)

Compounds of formula (I); which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).

Use of 19F NMR as a direct probe of Δ9 desaturase cryptoregiochemistry: A feasibility study

19F NMR can be used to monitor the relative efficiency with which various fluorinated aromatic sulfides are oxidized by the Δ9 desaturating system of Saccharomyces cerevisiae. Thus the sulfoxy acids produced from methyl S-(4-(trifluoromethyl)be

A liquid crystalline compound containing fluorine atom substituted alkyl group(s) and a liquid crystal composition

A liquid crystalline compound exhibiting a large Δ ε value, an electrical and chemical stability and a superior compatibility with existing liquid crystalline compounds, a liquid crystal composition containing the same, and a liquid crystal display element constructed by using the composition are provided,???which liquid crystalline compound is expressed by the formula (I), F-(CH2)n ―E-(CH2CH2) k―G-(CH2CH2)l―L-(CH2CH2) m―Z―Q―Y wherein n is an integer of 1 to 10; k, l and m each independently are an integer of 0 to 2; ring E is 1,4-cyclohexylene group or 1,4-phenylene group, wherein one or more H atoms on six-membered ring may be replaced by F atom(s); G and L each independently is a covalent bond or 1,4-cyclohexylene group or 1,4-phenylene group, wherein one or more H atoms on six-membered ring may be replaced by F atom(s); Q is covalent bond or -O-; Y is a fluoroalkyl group of 1 to 3C or F atom; but in the case where ring E is 1,4-cyclohexylene group and at least one of G and L is covalent bond, and in the case where Q is -O-, Y is not F atom.

Liquid crystalline compound and liquid crystal composition

A liquid crystalline compound expressed by the formula STR1 wherein R1 represents an alkyl group of 1 to 12 carbon atoms, and one or two not adjacent CH2 group excluding the terminal in this group may be replaced by --CO-- group, --O